FDA
-
-
-
-
-
-
-
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
-
-
-
-
-
-
-
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
-
-
-
-
-
-
-
Microbix Schedules Release of Results for Q4 Fiscal 2025
-
-
-
-
-
-
-
Microbix Addresses Cybersecurity Incident
-
-
-
-
-
-
-
MBX Biosciences begins phase 1 obesity drug trial
-
-
-
-
-
-
-
Microbix Exhibiting & Presenting at ADLM
-
-
-
-
-
-
-
Microbix Reports Results for Q2 Fiscal 2025
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

